Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 19/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364696 | 0.79 | SSTR4 (0.41) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL6653458 | 0.78 | GNAI3 (0.45) | SSTR4 | |
| SCHEMBL6653972 | 0.78 | GNAI3 (0.45) | SSTR4 | |
| SCHEMBL6651713 | 0.78 | GNAI3 (0.45) | SSTR4 | |
| SCHEMBL10908504 | 0.77 | SSTR4 (0.53) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL18664465 | 0.76 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL8860932 | 0.76 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL18664463 | 0.76 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL21902109 | 0.75 | SSTR4 (0.55) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20715370 | 0.75 | SSTR4 (0.55) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089963-B1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | disclosed |
| EP-1089963-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067201-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE | SMITHKLINE BEECHAM PLC (GB) | 1999-12-29 | — | — | WO | disclosed |